Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Lisa A. Carey(University of North Carolina at Chapel Hill), Clifford A. Hudis(American Society of Clinical Oncology), David W. Ollila(University of North Carolina at Chapel Hill), Carey K. Anders(Duke University), Maggie C.U. Cheang(Institute of Cancer Research), Brandelyn N. Pitcher(Statistical and Applied Mathematical Sciences Institute), Lyndsay N. Harris(National Institutes of Health), Douglas Weckstein(New Hampshire Hospital), Ian E. Krop(Yale Cancer Center), Charles M. Perou(University of North Carolina at Chapel Hill), N. Lynn Henry(University of Michigan), Michael D. Iglesia(Washington University in St. Louis), Baljit Singh(Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences), Eric P. Winer(University of Vermont), Donald A. Berry(Berry & Associates (United States)), Constance Cirrincione, William T. Barry(Harvard University), Katherine A. Hoadley(University of North Carolina at Chapel Hill)
Cited by 440
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
|Cell|2018|2.8k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k